Latest news with #Cytek
Business Upturn
2 days ago
- Business
- Business Upturn
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) — In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence. With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek Aurora Evo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include: Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. Small Particle Detection : Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. : Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. Automation Capabilities: Minimize instrument maintenance and maximize efficiency. An integrated plate loader supports multiple carrier types, offering flexible user modes for both low carryover and high-throughput needs. Automated startup and shutdown further streamline workflows, reducing downtime while ensuring high-quality, high-resolution data. Recognized as a pioneer in spectral flow cytometry, Cytek's distinctive approach is renowned for its profound influence on advancing the understanding of cell biology, immunology, oncology and targeted therapeutic methodologies. 'Cytek's Aurora and Northern Lights™ systems have helped revolutionize immunology research and single-cell analysis,' said Ming Yan, Ph.D., CTO of Cytek Biosciences. 'Over the years, we have continuously pushed the boundaries of what's possible in spectral flow cytometry. With this latest launch of the Cytek Aurora Evo system, we've integrated these advancements into a powerful, high-throughput workhorse that delivers an unmatched combination of performance, reliability, efficiency and ease of use – enabling more scientists to leverage the full potential of spectral flow cytometry.' The Cytek Aurora Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth. For more information, please visit About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava and Muse are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, and market opportunities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Quarterly Report on Form 10-Q filed on May 8, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080 [email protected]
Yahoo
2 days ago
- Health
- Yahoo
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
Improved Sample Throughput, Automation Capabilities and Updated Hardware Design Cytek Aurora™ Evo FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence. With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek Aurora Evo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include: Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. Small Particle Detection: Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. Automation Capabilities: Minimize instrument maintenance and maximize efficiency. An integrated plate loader supports multiple carrier types, offering flexible user modes for both low carryover and high-throughput needs. Automated startup and shutdown further streamline workflows, reducing downtime while ensuring high-quality, high-resolution data. Recognized as a pioneer in spectral flow cytometry, Cytek's distinctive approach is renowned for its profound influence on advancing the understanding of cell biology, immunology, oncology and targeted therapeutic methodologies. 'Cytek's Aurora and Northern Lights™ systems have helped revolutionize immunology research and single-cell analysis,' said Ming Yan, Ph.D., CTO of Cytek Biosciences. 'Over the years, we have continuously pushed the boundaries of what's possible in spectral flow cytometry. With this latest launch of the Cytek Aurora Evo system, we've integrated these advancements into a powerful, high-throughput workhorse that delivers an unmatched combination of performance, reliability, efficiency and ease of use – enabling more scientists to leverage the full potential of spectral flow cytometry.' The Cytek Aurora Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth. For more information, please visit About Cytek Biosciences, Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava and Muse are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, and market opportunities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Quarterly Report on Form 10-Q filed on May 8, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@ Investor Contact:Paul GoodsonHead of Investor RelationsCytek Biosciencespgoodson@ A photo accompanying this announcement is available at in to access your portfolio
Yahoo
4 days ago
- Business
- Yahoo
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference
FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. Cytek management is scheduled to participate in a fireside chat on Wednesday, June 11th at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the 'Investors' section of the company website at: About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™ and Cytek Aurora™ CS systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, and Guava are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@ Investor Contact:Paul GoodsonHead of Investor RelationsCytek Biosciencespgoodson@
Yahoo
29-04-2025
- Business
- Yahoo
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
Company to Conduct Demonstrations, Educational Workshops and Tutorials at Key Industry Events FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at CYTO 2025 and American Association of Immunologists' (AAI) IMMUNOLOGY2025. Designed to streamline workflows, accelerate discoveries, and enhance efficiency, FSP technology will be the focus of a variety of demonstrations, educational workshops and tutorials at these prominent industry gatherings. Flow cytometry plays a crucial role in both research and clinical studies, and Cytek is at the forefront of making this powerful technology more accessible and scalable. By empowering scientists to accelerate discovery and deliver deeper, more actionable insights, Cytek is unlocking new opportunities across high-growth areas like immunology, oncology, and cell therapy. As a pioneer in spectral flow cytometry, Cytek's differentiated platform is not only advancing scientific understanding but also expanding its footprint in a rapidly evolving market. IMMUNOLOGY2025May 3, 2025 – May 7, 2025Honolulu, HawaiiBooth: 801The American Association of Immunologists' (AAI) annual meeting has become the leading annual all-immunology event worldwide, bringing together a global community of immunologists. At this year's conference, Cytek will showcase its complete cell analysis solutions that enable scientists to advance their research, gain deeper insights, and fast-track discovery. The company's comprehensive, integrated suite of solutions includes the Cytek portfolio of instruments, reagents, Cytek® Cloud, software and services. Also at IMMUNOLOGY2025, Eleanor Kincaid, Ph.D., field applications manager, eastern U.S. for Cytek Biosciences, will host an exhibitor workshop. Titled 'A Robust Approach for In-Depth Characterization of Mouse Immune Responses Using the Cytek 24-Color Mouse Immunoprofiling Panel,' this workshop will take place on Sunday, May 4, 2025, from 1:15 p.m. – 2:00 p.m. CYTO 2025May 31, 2025 – June 4, 2025Denver, ColoradoBooth: 401CYTO 2025, the 38th annual Congress of the International Society for the Advancement of Cytometry, is a leading global conference that brings together the many facets of cytometry science and engineering in an inclusive and dynamic setting. At CYTO, Cytek, a Platinum sponsor of the conference, will showcase its technology, designed to accelerate scientific discovery. Built with the scientist in mind, Cytek's solutions continually evolve and expand to enhance the research experience. 'We're thrilled to be part of CYTO 2025, the industry's premier event, where the brightest minds in cytometry come together to shape the future of the field,' said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. 'As a leader in spectral flow cytometry, Cytek is committed to making this powerful technology more accessible than ever – enabling scientists to push the boundaries of discovery. By delivering innovative, flexible solutions, we're equipping researchers with the tools and knowledge they need to accelerate breakthroughs and drive the next era of scientific advancement.' For more information, please visit About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™ and Cytek Aurora™ CS systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, market opportunities and expansion. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could materially affect future results include, but are not limited to, global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Annual Report on Form 10-K filed on February 28, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@ Investor Contact:Paul GoodsonHead of Investor RelationsCytek Biosciencespgoodson@ in to access your portfolio
Yahoo
18-03-2025
- Business
- Yahoo
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System
Increasing Accessibility for Flow Cytometry Applications in Emerging and Established Markets Cytek Muse Micro FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek® Guava® Muse® cell analyzer, creating a next-generation instrument called the Cytek® Muse® Micro. The Muse Micro cell analyzer is an affordable option that simplifies flow cytometry while enhancing ease-of-use, precision and versatility. The Muse Micro system expands assay capabilities to penetrate established and emerging markets such as cell and gene therapy, drug discovery, pathway analysis, cell counting, viability, apoptosis, cellular stress and immune cell monitoring. Sophisticated cell analysis is no longer exclusive, complex, or expensive. Its intuitive touchscreen interface, easy-to-use software, and optimized 'Mix-and-Read' assays combine to streamline and simplify flow cytometry analyses. The Muse Micro cell analyzer is built on the legacy of the original Muse system – which was introduced in 2013 as the most compact flow cytometer the world had ever seen. The original Muse system has an extensive worldwide installed base and has been featured in thousands of publications since its inception. The new Muse Micro system is equipped with a 488 nm blue laser and offers five parameters, including forward and side scatter alongside three fluorescent channels. Its intuitive software interface and pre-optimized assay kits make routine assays – including cell count, viability, health, stress and population identification analyses – faster and more accessible than ever before. Cytek anticipates that the Muse Micro system will sustain the growth of the Muse reagent business by utilizing additional new channels. The Muse Micro cell analyzer is designed to meet the diverse needs of testing and research environments across a wide range of industries, including drug discovery, water quality testing, biopharma, bioprocessing and wine and beer production. Its compact design and user-friendly interface make it an ideal solution for both academic and industrial laboratories, where precise and reliable cell analysis is critical. Key features include: Compact design: Takes up minimal lab space, measuring just 8 in x 10 in (20 cm x 25 cm), without compromising performance. Advanced microcapillary technology: A high-precision displacement pump delivers accurate and precise cell counts, eliminating the need for calibration beads. Pre-optimized kits and modules: Streamlines routine assays with reliable, reproducible results and minimal setup time with additional kits in development. Simplified data acquisition and analysis: Includes Cytek InCyte™ software, empowering users to develop and run their own three-color assays. Affordable: Provides reliable flow cytometry analysis at a cost-effective price point, making it accessible to every lab. 'With the Cytek Muse Micro system, we are continuing Cytek's commitment to making advanced cellular instrumentation accessible to more labs,' said Ming Yan, Ph.D., CTO of Cytek Biosciences. 'Traditional flow cytometry systems can be cost-prohibitive and workflow-intensive, limiting their use to only the most well-funded, deeply-staffed labs. By leveraging our breakthrough technologies, we aim to transcend these barriers – streamlining workflows and delivering biological clarity at levels previously available to only a select few. The Muse Micro cell analyzer opens new market opportunities for Cytek by enabling smaller labs, emerging markets, and resource-limited facilities to access high-quality flow cytometry at an affordable price. This is a crucial step in expanding our reach and empowering a broader range of researchers worldwide.' The Muse Micro cell analyzer is available now. For more information, please visit About Cytek Biosciences, Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™ and Cytek Aurora™ CS systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava, Muse and InCyte are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, market opportunities and expansion, and growth of the Muse reagent business. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties relating to global economic, political and market conditions; competition; market acceptance of Cytek's current and potential products; Cytek's dependence on certain sole and single source suppliers; Cytek's ability to manage the growth and complexity of its organization; Cytek's ability to manage relationships with key customers and suppliers; Cytek's ability to retain key employees; and Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Annual Report on Form 10-K filed on February 28, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@ Investor Contact:Paul GoodsonHead of Investor RelationsCytek Biosciencespgoodson@ A photo accompanying this announcement is available at in to access your portfolio
